Thalidomide-Piperazine-Piperidine is primarily used in the field of medicinal chemistry and drug development. Its structure, combining thalidomide with piperazine and piperidine moieties, makes it a candidate for designing novel therapeutic agents. It is particularly explored for its potential in targeting cancer and inflammatory diseases due to its ability to modulate immune responses and inhibit angiogenesis. Researchers are investigating its application in treating conditions like multiple myeloma and other malignancies, leveraging its mechanism of action to disrupt tumor growth and inflammation pathways. Additionally, its derivatives are being studied for their role in neurodegenerative diseases, where they may help regulate protein misfolding and aggregation. The compound's versatility in drug design makes it a valuable scaffold for developing targeted therapies with improved efficacy and reduced side effects.